Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing an exclusive, worldwide License and Commercialisation Agreement with QIMR Berghofer for a SETDB1-targeted epigenetic platform.
Under the agreement Kazia will pay an upfront license fee of $1,390,000 and a tiered revenue-sharing percentage on commercialization receipts; Kazia intends to advance the SETDB1 program in preclinical work toward IND-enabling studies in parallel with its PD-L1 degrader program.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares pursuant to the Registration Statement on Form F-1, as supplemented by a Form 6-K furnished April 13, 2026.
The April 10, 2026 Form 6-K discloses Kazia's entry into an exclusive, worldwide license with QIMR Berghofer for a SETDB1-targeted epigenetic platform. Under the Agreement Kazia will pay an upfront license fee of $1,390,000 and agreed revenue-sharing percentages on commercialization revenue; Kazia plans IND-enabling work and to use commercially reasonable efforts to develop at least one product under the license.
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares in connection with its Form F-1 registration.
The supplement attaches a Form 6-K describing Kazia's April 10, 2026 license and commercialisation agreement with QIMR Berghofer, under which Kazia licensed a SETDB1-targeted epigenetic platform and agreed to pay an upfront license fee of $1,390,000. The Form 6-K and attached press release describe the licensed lead candidate MSETC, preclinical status, a projected $6 million combined cost to advance two preclinical programs to IND readiness over 18 months, and a tiered revenue-sharing structure with no clinical or regulatory milestone obligations.
Kazia Therapeutics Limited has entered a License and Commercialisation Agreement with QIMR Berghofer, gaining an exclusive worldwide license to develop and commercialize cancer therapies based on a proprietary SETDB1-targeted epigenetic platform.
Kazia will pay an upfront license fee of $1,390,000 and share a percentage of future commercialization revenue, with rates linked to the development stage at which any product is out-licensed. The lead candidate, MSETC, is a highly selective bicyclic peptide discovered using an AI-integrated epigenetic drug discovery engine and is designed to restore immune signaling in tumors resistant to immunotherapy.
The company plans to advance the SETDB1 and PD-L1 degrader programs through IND-enabling studies over about 18 months at a combined expected cost of approximately $6 million, leveraging shared CRO resources and Australian R&D tax incentives. Kazia views the SETDB1 platform as complementary to its existing oncology pipeline, which includes paxalisib and EVT801.
Kazia Therapeutics Ltd chief executive John E. Friend II reports his holdings of an American Depositary Share (ADS) option covering 30,000 ADSs. The ADS option was granted on July 22, 2024 at an exercise price of $18.85 per ADS and expires on July 22, 2027. It vests in equal quarterly installments over three years beginning April 22, 2024, contingent on continued service. This amended Form 3 corrects the exercise price of the previously reported ADS option.
Kazia Therapeutics executive David Cain filed an initial ownership report showing he holds several stock option awards. These include options over 5,000 American Depositary Shares at an exercise price of $19.0000 and 100,000 ADS at $8.0000, plus options over 100,000 and 400,000 Ordinary Shares at exercise prices of $0.6651 and $0.1061. The options vest in scheduled annual or quarterly installments, contingent on his continued service, and expire between February 1, 2027 and July 22, 2027.
Kazia Therapeutics Limited filed a prospectus supplement to update its Form F-1 registration for 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares, referencing a Form 6-K dated March 31, 2026. The supplement attaches a March 27, 2026 investor presentation and fact sheet and notes a board change: Chairman Bryce Carmine resigned effective March 31, 2026, reducing the board from four to three directors. The company reported the re-election of Steven Coffey with 1,050,412,780 votes for.
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 Ordinary Shares, and furnishes a Form 6-K dated March 31, 2026. The supplement attaches an investor presentation and fact sheet dated March 27, 2026 and notes the ADS last sale price of $7.31 per ADS.
The Form 6-K reports the resignation of Chairman Bryce Carmine effective March 31, 2026, a reduction in Board size from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and shareholder re-election of Steven Coffey at the AGM.
Kazia Therapeutics Limited filed a prospectus supplement updating its Form F-1 registration to reflect a Form 6-K furnished March 31, 2026. The supplement covers 266,666 ADSs representing 133,333,000 Ordinary Shares and states the ADSs trade on Nasdaq under the symbol KZIA. The company reported the March 25, 2026 Annual General Meeting approved the re-election of Steven Coffey with 1,050,412,780 votes for, and noted the resignation of Chairman Bryce Carmine effective March 31, 2026, reducing the Board from four to three directors.
Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares (ADSs). The supplement attaches a Form 6-K dated March 31, 2026 and updates the Prospectus dated December 23, 2025.
The Form 6-K discloses the resignation of Chairman Bryce Carmine effective March 31, 2026, the Board shrinking from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and AGM vote results re‑electing Steven Coffey (1,050,412,780 for; 3,637,588 against; 1,289,127 abstain). The ADSs trade on Nasdaq under symbol KZIA (last reported sale $7.31 per ADS).